Correction to: The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program “CASCADE” (PLOS Medicine, (2016), 13, 12, (e1002204), 10.1371/journal.pmed.1002204);The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program “CASCADE”

PLoS Medicine

Volumn 13, Issue 12, 2016, Pages

  Savas, Peter ^a   Teo, Zhi Ling ^a   Lefevre, Christophe ^b,c   Flensburg, Christoffer ^b,c   Caramia, Franco ^a   Alsop, Kathryn ^a   Mansour, Mariam ^a   Francis, Prudence A ^a   Thorne, Heather A ^a   Silva, Maria Joao ^a   Kanu, Nnennaya ^d   Dietzen, Michelle ^d   Rowan, Andrew ^e   Kschischo, Maik ^f   Fox, Stephen ^a   Bowtell, David D ^a,g   Dawson, Sarah Jane ^a,g   Speed, Terence P ^b,g   Swanton, Charles ^d,e   Loi, Sherene ^a,g  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^f UNIVERSITY OF APPLIED SCIENCES KOBLENZ   (Germany)

^g UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA KINASE; CAPECITABINE; CARBOPLATIN; CHLOROPLAST DNA; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERIBULIN; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; FIBROBLAST GROWTH FACTOR RECEPTOR 4; FLUOROURACIL; FULVESTRANT; GEMCITABINE; LETROZOLE; METHOTREXATE; NAVELBINE; PACLITAXEL; PROGESTERONE; TAMOXIFEN; TRASTUZUMAB;

ADULT; ARTICLE; AUTOPSY; CASE REPORT; CHROMOSOMAL INSTABILITY; COPY NUMBER VARIATION; DNA EXTRACTION; FEMALE; GENE FREQUENCY; GENETIC HETEROGENEITY; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MASTECTOMY; METASTATIC BREAST CANCER; MULTIPLEX POLYMERASE CHAIN REACTION; OVARIECTOMY; RELAPSE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TETRAPLOIDY; TRIPLOIDY; BREAST TUMOR; EXOME; GENETICS; HIGH THROUGHPUT SEQUENCING; MUTATION; PARTICIPATORY RESEARCH; PATHOLOGY;

ADULT; AUTOPSY; BREAST NEOPLASMS; COMMUNITY-BASED PARTICIPATORY RESEARCH; EXOME; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 85007518478     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1002302     Document Type: Erratum

References (60)

1. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, et al. Mutational evolution in a lobular breast tumor profiled at single nucleotide resolution. Nature. 2009;461: 809–13. doi: 10.1038/nature0848919812674
2. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 2010;464: 999–1005. doi: 10.1038/nature0898920393555
3. Eirew P, Steif A, Khattra J, Ha G, Yap D, Farahani H, et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature. 2014;518: 422–426. doi: 10.1038/nature1395225470049
4. Murtaza M, Dawson S-J, Pogrebniak K, Rueda OM, Provenzano E, Grant J, et al. Multifocal clonal evolution characterized using circulating tumor DNA in a case of metastatic breast cancer. Nat Commun. 2015;6: 8760. doi: 10.1038/ncomms976026530965
5. Juric D, Castel P, Griffith M, Griffith OL, Won HH, Ellis H, et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature. 2014;518: 240–244. doi: 10.1038/nature1394825409150
6. Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, Van Loo P, et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med. 2015;21: 751–9. doi: 10.1038/nm.388626099045
7. Janiszewska M, Liu L, Almendro V, Kuang Y, Paweletz C, Sakr RA, et al. In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nat Genet. 2015;47: 1212–9. doi: 10.1038/ng.339126301495
8. Gao R, Davis A, McDonald TO, Sei E, Shi X, Wang Y, et al. Punctuated copy number evolution and clonal stasis in triple-negative breast cancer. Nat Genet. 2016;48: 1119–1130. doi: 10.1038/ng.364127526321
9. Alsop K, Thorne H, Sandhu S, Hamilton A, Mintoff C, Christie E, et al. A community-based model of rapid autopsy in end-stage cancer patients. Nat Biotechnol. 2016;34: 1010–1014. doi: 10.1038/nbt.367427617737
10. Martin M, Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet.journal. 2011;17: 10–12.
11. Li H, Durbin R, Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25: 1754–60. doi: 10.1093/bioinformatics/btp32419451168
12. Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A, et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinforma. 2013;43: 11.10.1–33.
13. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31: 213–9. doi: 10.1038/nbt.251423396013
14. Lai Z, Markovets A, Ahdesmaki M, Chapman B, Hofmann O, McEwen R, et al. VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res. 2016;44: e108–e108. doi: 10.1093/nar/gkw22727060149
15. Ye K, Schulz MH, Long Q, Apweiler R, Ning Z, Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics. 2009;25: 2865–71. doi: 10.1093/bioinformatics/btp39419561018
16. Wang K, Li M, Hakonarson H, ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38: e164. doi: 10.1093/nar/gkq60320601685
17. Auton A, Abecasis GR, Altshuler DM, Durbin RM, Abecasis GR, Bentley DR, et al. A global reference for human genetic variation. Nature. 2015;526: 68–74. doi: 10.1038/nature1539326432245
18. NHLBI GO Exome Sequencing Project (ESP). Exome Variant Server [Internet]. [cited 18 Oct 2016]. http://evs.gs.washington.edu/EVS/
19. Shen R, Seshan VE, FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 2016;44: e131. doi: 10.1093/nar/gkw52027270079
20. Staaf J, Vallon-Christersson J, Lindgren D, Juliusson G, Rosenquist R, Höglund M, et al. Normalization of Illumina Infinium whole-genome SNP data improves copy number estimates and allelic intensity ratios. BMC Bioinformatics. 2008;9: 409. doi: 10.1186/1471-2105-9-40918831757
21. Yau C, Mouradov D, Jorissen R, Colella S, Mirza G, Steers G, et al. A statistical approach for detecting genomic aberrations in heterogeneous tumor samples from single nucleotide polymorphism genotyping data. Genome Biol. 2010;11: R92. doi: 10.1186/gb-2010-11-9-r9220858232
22. Bengtsson H, Neuvial P, Speed TP, TumorBoost: normalization of allele-specific tumor copy numbers from a single pair of tumor-normal genotyping microarrays. BMC Bioinformatics. 2010;11: 245. doi: 10.1186/1471-2105-11-24520462408
23. Olshen AB, Bengtsson H, Neuvial P, Spellman PT, Olshen RA, Seshan VE, Parent-specific copy number in paired tumor-normal studies using circular binary segmentation. Bioinformatics. 2011;27: 2038–46. doi: 10.1093/bioinformatics/btr32921666266
24. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015;43: D805–11. doi: 10.1093/nar/gku107525355519
25. Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell. 2015;163: 506–19. doi: 10.1016/j.cell.2015.09.03326451490
26. Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J, A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46: 310–5. doi: 10.1038/ng.289224487276
27. Miller ML, Reznik E, Gauthier NP, Aksoy BA, Korkut A, Gao J, et al. Pan-Cancer Analysis of Mutation Hotspots in Protein Domains. Cell Syst. 2015;1: 197–209. doi: 10.1016/j.cels.2015.08.01427135912
28. Chang MT, Asthana S, Gao SP, Lee BH, Chapman JS, Kandoth C, et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol. 2016;34: 155–63. doi: 10.1038/nbt.339126619011
29. Xin J, Mark A, Afrasiabi C, Tsueng G, Juchler M, Gopal N, et al. High-performance web services for querying gene and variant annotation. Genome Biol. 2016;17: 91. doi: 10.1186/s13059-016-0953-927154141
30. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G, GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12: R41. doi: 10.1186/gb-2011-12-4-r4121527027
31. Sanchez-Garcia F, Villagrasa P, Matsui J, Kotliar D, Castro V, Akavia U-D, et al. Integration of Genomic Data Enables Selective Discovery of Breast Cancer Drivers. Cell. 2014;159: 1461–75. doi: 10.1016/j.cell.2014.10.04825433701
32. Flensburg C. superFREQ [Internet]. 2016 [cited 18 Oct 2016]. https://github.com/ChristofferFlensburg/superFreq
33. Law CW, Chen Y, Shi W, Smyth GK, voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 2014;15: R29. doi: 10.1186/gb-2014-15-2-r2924485249
34. Roth A, Khattra J, Yap D, Wan A, Laks E, Biele J, et al. PyClone: statistical inference of clonal population structure in cancer. Nat Methods. 2014;11: 396–398. doi: 10.1038/nmeth.288324633410
35. Niknafs N, Beleva-Guthrie V, Naiman DQ, Karchin R, Nowell P, Greaves M, Morris Q, et al. SubClonal Hierarchy Inference from Somatic Mutations: Automatic Reconstruction of Cancer Evolutionary Trees from Multi-region Next Generation Sequencing. PLoS Comput Biol. 2015;11: e1004416. doi: 10.1371/journal.pcbi.100441626436540
36. Lawrence M, Huber W, Pagès H, Aboyoun P, Carlson M, Gentleman R, et al. Software for Computing and Annotating Genomic Ranges. PLoS Comput Biol. 2013;9: e1003118. doi: 10.1371/journal.pcbi.100311823950696
37. Rosenthal R, McGranahan N, Herrero J, Taylor BS, Swanton C, DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 2016;17: 31. doi: 10.1186/s13059-016-0893-426899170
38. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500: 415–21. doi: 10.1038/nature1247723945592
39. COSMIC. Signatures of Mutational Processes in Human Cancer [Internet]. [cited 18 Oct 2016]. http://cancer.sanger.ac.uk/cosmic/signatures
40. Fumagalli D, Wilson TR, Salgado R, Lu X, Yu J, O’Brien C, et al. Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. Ann Oncol Off J Eur Soc Med Oncol. 2016;27: 1860–6.
41. Griffith M, Miller CA, Griffith OL, Krysiak K, Skidmore ZL, Ramu A, et al. Optimizing Cancer Genome Sequencing and Analysis. Cell Syst. 2015;1: 210–223. doi: 10.1016/j.cels.2015.08.01526645048
42. El-Kebir M, Satas G, Oesper L, Raphael BJ, Agarwala R, Fernández-Baca D, et al. Inferring the Mutational History of a Tumor Using Multi-state Perfect Phylogeny Mixtures. Cell Syst. 2016;3: 43–53. doi: 10.1016/j.cels.2016.07.00427467246
43. Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, et al. The evolutionary history of lethal metastatic prostate cancer. Nature. 2015;520: 353–357. doi: 10.1038/nature1434725830880
44. Marusyk A, Tabassum DP, Altrock PM, Almendro V, Michor F, Polyak K, Non-cell-autonomous driving of tumor growth supports sub-clonal heterogeneity. Nature. 2014;514: 54–8. doi: 10.1038/nature1355625079331
45. Kawate H, Landis DM, Loeb LA, Distribution of mutations in human thymidylate synthase yielding resistance to 5-fluorodeoxyuridine. J Biol Chem. 2002;277: 36304–11. doi: 10.1074/jbc.M20495620012147691
46. Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45: 1439–1445. doi: 10.1038/ng.282224185512
47. Fribbens C, O’Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, et al. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. J Clin Oncol. 2016;34: 2961–8. doi: 10.1200/JCO.2016.67.306127269946
48. Patch A-M, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, et al. Whole–genome characterization of chemoresistant ovarian cancer. Nature. 2015;521: 489–494. doi: 10.1038/nature1441026017449
49. Morrissy AS, Garzia L, Shih DJH, Zuyderduyn S, Huang X, Skowron P, et al. Divergent clonal selection dominates medulloblastoma at recurrence. Nature. 2016;529: 351–7. doi: 10.1038/nature1647826760213
50. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381: 805–16. doi: 10.1016/S0140-6736(12)61963-123219286
51. Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, et al. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med. 2016;375: 209–219. doi: 10.1056/NEJMoa160470027264120
52. Hong MKH, Macintyre G, Wedge DC, Van Loo P, Patel K, Lunke S, et al. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat Commun. 2015;6: 6605. doi: 10.1038/ncomms760525827447
53. Légaré S, Cavallone L, Mamo A, Chabot C, Sirois I, Magliocco A, et al. The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers. Cancer Res. 2015;75: 4351–63. doi: 10.1158/0008-5472.CAN-14-347526297734
54. Lee AJX, Endesfelder D, Rowan AJ, Walther A, Birkbak NJ, Futreal PA, et al. Chromosomal instability confers intrinsic multidrug resistance. Cancer Res. 2011;71: 1858–70. doi: 10.1158/0008-5472.CAN-10-360421363922
55. Chen G, Bradford WD, Seidel CW, Li R, Hsp90 stress potentiates rapid cellular adaptation through induction of aneuploidy. Nature. 2012;482: 246–50. doi: 10.1038/nature1079522286062
56. Notta F, Chan-Seng-Yue M, Lemire M, Li Y, Wilson GW, Connor AA, et al. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature. 2016;538: 378–382. doi: 10.1038/nature1982327732578
57. Swanton C, McGranahan N, Starrett GJ, Harris RS, APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. Cancer Discov. 2015;5: 704–12. doi: 10.1158/2159-8290.CD-15-034426091828
58. Henderson S, Chakravarthy A, Su X, Boshoff C, Fenton TR, APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep. 2014;7: 1833–41. doi: 10.1016/j.celrep.2014.05.01224910434
59. Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2015;372: 724–734. doi: 10.1056/NEJMoa141351325693012
60. Erdmann J, Trace elements: Innovative biopsy programs map how cancer spreads. Nat Med. 2016;22: 963–5. doi: 10.1038/nm0916-96327603126